Clinical Trials Browser

Disease × ofatumumab × Clear all

NCT01613300 2021-05-26

Study of OFATUMUMAB as Part of the Scheme of Reduced Intensity Conditioning in High Risk Non-Hodgkin Lymphoma B Patients

Phase 2 Completed

Disease, Lymphoma, B-Cell